LONDON (Alliance News) - BATM Advanced Communications Ltd Wednesday said the Pathogenic Waste Treatment Sterilisation unit of its biomedical division has been awarded its first significant contract for its biological waste solution with a manufacturer of vaccines for animal health.
The medical technology company said it will receive an initial order of USD320,000 for the waste product at one of the customer's production sites in Europe this year, which is expected to grow to USD1.2 million following further orders in its European and US-based production sites in 2016.
The project will work to automate the safe disposal of bio-hazardous waste that is created during the manufacturing of vaccines, and will enable customers to treat the waste on site, mitigating the risk of cross-contamination.
"We are very pleased with the award of this new contract, which represents the first substantial order for our new biological waste solution for the biopharma industry. This new solution is the most cost effective and efficient method of treating and disposing of bio-hazardous waste available today. As such, we expect to receive growing demand for this system whilst continuing to innovate to provide further global market-leading waste treatment solutions in the biopharma and agricultural industries, to complement our established position in the medical industry," Chief Executive Zvi Marom said in a statement.
BATM shares were untraded early Wednesday. The stock last traded at 14.75 pence.
By Karolina Kaminska; karolinakaminska@alliancenews.com @KarolinaAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Batm Advanced (BVC)